NCT03068169

Brief Summary

Cardiovascular diseases (CVD) are associated with high healthcare costs, as well as are a leading cause of mortality and hospitalizations. The main challenge for today's researchers is to develop new technologies, which may help to improve diagnosis of CVD, thereby reducing healthcare costs and quality of patients' lives. Non-invasive wearable electronics offer new capabilities for the diagnosis and management of patients with CVD. Several reports with wearable electronics have been published, in which achieved very positive results with high accuracy. Aim of our study is to show utility of biomedical shirt-based ECG monitoring of patients with CVD in different clinical situations using Nuubo® ECG (nECG) system.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
220

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2017

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 10, 2017

Completed
19 days until next milestone

First Posted

Study publicly available on registry

March 1, 2017

Completed
4 months until next milestone

Study Start

First participant enrolled

June 15, 2017

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2018

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
Last Updated

June 8, 2017

Status Verified

June 1, 2017

Enrollment Period

1.2 years

First QC Date

February 10, 2017

Last Update Submit

June 7, 2017

Conditions

Keywords

remote ECGatrial fibrillationcardiac rehabilitationcardiac resynchronization therapysupraventricular tachycardia

Outcome Measures

Primary Outcomes (4)

  • Association between early recurrences of atrial tachyarrhythmias (ERAT) during blanking period on long-term effectiveness of pulmonary veins isolation (PVI) using nECG shirt.

    Assessment of the rationale for the use of blanking period and to determine whether the early recurrences of atrial tachyarrhythmias (ERAT) burden influences on long-term effectiveness of pulmonary veins isolation (PVI) using nECG shirt. The study might demonstrate which patients with ERAT remain at risk of long-term recurrence of atrial fibrillation (AF).

    13 months

  • Assessment of the usefulness of nECG shirt in detection of fusion and pseudo-fusion beats in cardiac resynchronization therapy (CRT) recipients.

    7 months

  • Assessment of the impact of the use of a pedometer combined with nECG shirt on the level of daily physical activity and its intensity.

    12 month

  • Creation of an algorithm based on nECG monitoring using wearable shirt to differentiate atrioventricular reentry tachycardia (AVRT) with atrioventricular nodal reentry tachycardia (AVNRT) in pediatric patients suffering from supraventricular tachycardia.

    1 month

Secondary Outcomes (1)

  • Assessment of the influence of CRT implantation on amount of physical activity measured by nECG shirt.

    7 month

Eligibility Criteria

Age5 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study will be consisted of four independent patient groups: 30 patients with paroxysmal AF treated with PVI; 30 patients scheduled for CRT implantation; 120 patients after early post-infarction ambulatory cardiac rehabilitation; 40 patients, between 5 to 18 years old, with diagnosed SVT and who are qualified for electrophysiological study (EPS).

You may qualify if:

  • PVI in a patient with paroxysmal AF
  • years old

You may not qualify if:

  • BMI ≥35 kg/m2
  • Chronic inflammatory disease, severe chronic kidney disease,
  • Active cancer, and a period of 5 years from the end of treatment
  • Use of antiarrhythmic agents after PVI
  • Persistent AF
  • Previous PVI
  • The size of the chest that prevents wearing biomedical shirt
  • Contraindications to wear biomedical shirt (structural disease of the chest, skin diseases, allergy for materials used in ECG shirts)
  • CRT recipients
  • \> 18 years old
  • Meeting the current European Society of Cardiology Guidelines indications for CRT implantation (including upgrades)
  • Chest size which make impossible to wear nECG shirt
  • Contraindications to wear biomedical shirt (structural disease of the chest, skin diseases, allergy for materials used in ECG shirts)
  • Patients during cardiac rehabilitation after myocardial infarction
  • Patients within 3 months after myocardial infarction, after completed early post-infarction ambulatory cardiac rehabilitation
  • +27 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Department of Pediatric Cardiology and General Pediatrics, Medical University of Warsaw

Warsaw, Masovian Voivodeship, 02-091, Poland

RECRUITING

Department of Clinical Nursing, Medical University of Warsaw

Warsaw, Masovian Voivodeship, 02-097, Poland

NOT YET RECRUITING

Paweł Balsam

Warsaw, Masovian Voivodeship, 02-097, Poland

NOT YET RECRUITING

Related Publications (1)

  • Balsam P, Lodzinski P, Tyminska A, Ozieranski K, Januszkiewicz L, Glowczynska R, Wesolowska K, Peller M, Pietrzak R, Ksiazczyk T, Borodzicz S, Koltowski L, Borkowski M, Werner B, Opolski G, Grabowski M. Study design and rationale for biomedical shirt-based electrocardiography monitoring in relevant clinical situations: ECG-shirt study. Cardiol J. 2018;25(1):52-59. doi: 10.5603/CJ.a2017.0102. Epub 2017 Aug 25.

MeSH Terms

Conditions

Atrial FibrillationTachycardia, Supraventricular

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsTachycardiaCardiac Conduction System Disease

Study Officials

  • Renata Główczyńska, PhD

    1st Department of Cardiology Medical University of Warsaw

    PRINCIPAL INVESTIGATOR
  • Paweł Balsam, PhD

    1st Department of Cardiology Medical University of Warsaw

    PRINCIPAL INVESTIGATOR
  • Piotr Lodziński, PhD

    1st Department of Cardiology Medical University of Warsaw

    PRINCIPAL INVESTIGATOR
  • Marcin Grabowski, PhD

    1st Department of Cardiology Medical University of Warsaw

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Paweł Balsam, PhD

CONTACT

Piotr Lodziński, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

February 10, 2017

First Posted

March 1, 2017

Study Start

June 15, 2017

Primary Completion

September 1, 2018

Study Completion

December 31, 2018

Last Updated

June 8, 2017

Record last verified: 2017-06

Data Sharing

IPD Sharing
Will share

Data will be available for meta-analysis

Locations